Effects of Nifedipine on Hepatic Drug Oxidation

Abstract

To determine whether inhibition of drug oxidation is a general property of all calcium antagonist drugs or just of a few, we measured effects of therapeutic doses of nifedipine on antipyrine biotransformation. Antipyrine was administered in random order to 10 subjects while drug-free and while taking nifedipine 30 mg 3 times daily. Total antipyrine clearance (means ± SE, 43.1 ± 4.8 control vs. 50.4 ± 6.5 ml/min; NS) tended to increase but not significantly. Elimination half-life decreased slightly (13.7 ± 1.0 control vs. 11.7 ± 0.9; p < 0.05). Antipyrine metabolite excretion, measured to evaluate selective oxidative pathways, was unaffected by concurrent nifedipine administration. Nifedipine in therapeutic doses had no effect on antipyrine oxidation, unlike verapamil and diltiazem, both of which inhibit hepatic drug oxidation. Inhibition of drug oxidation appears not to be a general property of calcium antagonist drugs.

Determining the applicable law for breach of competition claims in the Rome II Regulation and the need for effective consumer collective redress

“…108 As Dickinson has observed vis-à-vis Recital 21, 'the special rule in Article 6 is not an exception to the general rule in Article 4(1) but rather a clarification of it.' 109 The dual purpose of the 'effects test' 110 approach used to determine the applicable law rules for unfair competition is a 'market-orientated' 111 3. (a) The law applicable to a non-contractual obligation arising out of a restriction of competition shall be the law of the country where the market is, or is likely to be, affected.…”

Nifedipine for Epilepsy? A Double‐Blind, Placebo‐Controlled Trial

“…It does not inhibit drug metabolism (Bauer et al, 1986;Dickinson et al, 1988), and in a pilot open study appeared to reduce seizure frequency without altering anticonvulsant concentrations (Larkin et al, 1988). It does not inhibit drug metabolism (Bauer et al, 1986;Dickinson et al, 1988), and in a pilot open study appeared to reduce seizure frequency without altering anticonvulsant concentrations (Larkin et al, 1988).…”

“…Nifedipine (NFD) is a dihydropyridine that has been in widespread clinical use for the treatment of hypertension and angina for many years. It does not inhibit drug metabolism (Bauer et al, 1986;Dickinson et al, 1988), and in a pilot open study appeared to reduce seizure frequency without altering anticonvulsant concentrations (Larkin et al, 1988). The anticonvulsant efficacy of NFD in refractory epilepsy was initially supported anecdotally (Sander and Shorvon, 1988), although more recent results with the drug by the same group have been disappointing (Sander and Trevisol-Bittencourt, 1990).…”